Natco Pharma launches Tamiflu generic capsules in US
Natco Pharma has launched generic Tamiflu capsules, used for the treatment of influenza, in the American market after the final nod from the US health regulator in August this year. In a filing to... Natco Launches the First Generic equivalent of Tamiflu Capsules in the USA Market
Natco Pharma Ltd has informed BSE regarding a Press Release dated December 12, 2016 titled "Natco Launches the First Generic equivalent of Tamiflu Capsules in the USA Market". Natco gets USFDA nod for anti-sleep tablets
Armodafinil treats daytime sleepiness linked to sleep apnea, narcolepsy and shift work disorder; generic equivalent in the US had sales of $480 mn in 2015 Natco receives Final Approval for Generic Armodafinil Tablets for USA Market
Natco Pharma Ltd has informed BSE regarding a Press Release dated November 29, 2016, titled "Natco receives Final Approval for Generic Armodafinil Tablets for USA Market". Natco Pharma gets USFDA nod for generic Budesonide capsules
Drug firm Natco Pharma has received final approval from the US health regulator for generic version of Budesonide capsules used for the treatment of active Crohn's disease for the American... Natco Receives Final approval for generic Budesonide Capsules, 3 mg, for USA market
Natco Pharma Ltd has informed BSE regarding a Press Release dated November 24, 2016 titled "Natco Receives Final approval for generic Budesonide Capsules, 3 mg, for USA market". Natco Pharma lines up product filings; greenfield formulations facility coming up in Vizag
Natco Pharma has lined up a few product filings in the current financial year. According to its Vice Chairman & Chief Executive Officer Rajeev Nannapaneni, Natco has a target for six or seven... Presentation made to analysts/investors
Natco Pharma Ltd has informed BSE regarding "Submission of Presentation made to analysts/investors". Transcript of Conference Call
Natco Pharma Ltd has submitted to BSE a copy of the transcript of the Conference Call held on November 15, 2016.
Natco Pharma's Q2 net profit doubles to Rs66 crore
Natco Pharma's formulations business, which accounts for a lion's share of its revenue, grew 85% to Rs370.1 crore